Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

FDA Off-Label Use

Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

DISCLOSURE STATEMENTS:

Absence of Relevant Financial Relationships

The following planners, faculty, and others in control of educational content have no relevant financial relationships with ineligible companies.

Off-label/unapproved drug uses or products are mentioned within this activity.

Planning committee:
Gretchen Brummel, PharmD, BCPS
Consulting Solutions Director
Vizient

Michelle Smith, PharmD, BCPS
Pharmacy Executive, MWPC Pharmacy Network
Vizient

Presenters:
Amanda Frick, PharmD, BCPS
Sr Clinical Manager
Vizient

Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Vizient

John Schoen, PharmD, BCPS
Sr. Clinical Manager of Drug Information
Vizient